GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Lucid Diagnostics Inc (NAS:LUCD) » Definitions » 6-1 Month Momentum %

Lucid Diagnostics (Lucid Diagnostics) 6-1 Month Momentum % : -30.55% (As of May. 03, 2024)


View and export this data going back to 2021. Start your Free Trial

What is Lucid Diagnostics 6-1 Month Momentum %?

6-1 Month Momentum % is the total return of the stock from 6-month ago to 1-month ago. As of today (2024-05-03), Lucid Diagnostics's 6-1 Month Momentum % is -30.55%.

The industry rank for Lucid Diagnostics's 6-1 Month Momentum % or its related term are showing as below:

LUCD's 6-1 Month Momentum % is ranked worse than
84.25% of 870 companies
in the Medical Devices & Instruments industry
Industry Median: -2.105 vs LUCD: -30.55

Competitive Comparison of Lucid Diagnostics's 6-1 Month Momentum %

For the Medical Devices subindustry, Lucid Diagnostics's 6-1 Month Momentum %, along with its competitors' market caps and 6-1 Month Momentum % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Lucid Diagnostics's 6-1 Month Momentum % Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Lucid Diagnostics's 6-1 Month Momentum % distribution charts can be found below:

* The bar in red indicates where Lucid Diagnostics's 6-1 Month Momentum % falls into.



Lucid Diagnostics  (NAS:LUCD) 6-1 Month Momentum % Calculation

6-1 Month Momentum % is calculated as following:

6-1 Month Momentum %=( Price 1-month ago / Price 6-month ago - 1 ) * 100 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Lucid Diagnostics  (NAS:LUCD) 6-1 Month Momentum % Explanation

Momentum investing is a trading strategy in which investors buy securities that are rising and sell before the prices start to go back down. The 6-1 Month Momentum % measures the total return to a stock over the past six months, but ignores the previous month.

The reason why the most recent month’s return dropped related to the short-term reversal effect associated with momentum. There is an academic finding that short-term momentum actually has a reversal effect, whereby the previous winners (measured over the past months) do poorly the next month, while the previous losers do well the next month. In order to eliminate the short-term reversal effect, the previous month return was not included in this calculation.


Lucid Diagnostics 6-1 Month Momentum % Related Terms

Thank you for viewing the detailed overview of Lucid Diagnostics's 6-1 Month Momentum % provided by GuruFocus.com. Please click on the following links to see related term pages.


Lucid Diagnostics (Lucid Diagnostics) Business Description

Traded in Other Exchanges
N/A
Address
360 Madison Avenue, 25th Floor, New York, NY, USA, 10017
Lucid Diagnostics Inc is a commercial-stage medical diagnostics technology company focused on the millions of patients with gastroesophageal reflux disease, also known as chronic heartburn, acid reflux, or simply reflux, who are at risk of developing esophageal precancer and cancer, specifically highly lethal esophageal adenocarcinoma. Its products include EsoCheck and EsoGuard.
Executives
Stanley Lapidus director 101 HARTWELL AVE., LEXINGTON MA 02421
Debra White director C/O PAVMED INC., ONE GRAND CENTRAL PLACE, SUITE 4600, NEW YORK NY 10165
Michael Adam Gordon officer: General Counsel ONE GRAND CENTRAL PLACE, SUITE 4600, NEW YORK NY 10165
Shaun O'neil officer: Chief Operating Officer ONE GRAND CENTRAL PLACE, SUITE 4600, NEW YORK NY 10165
Pavmed Inc. 10 percent owner 360 MADISON AVENUE, 25TH FLOOR, NEW YORK NY 10017
Lishan Aklog director, officer: Chief Executive Officer 420 LEXINGTON AVENUE, SUITE 300, NEW YORK NY 10171
Dennis M Mcgrath officer: Chief Financial Officer C/O PAVMED INC., ONE GRAND CENTRAL PLACE, STE. 4600, NEW YORK NY 10165
Ronald M Sparks director 420 LEXINGTON AVENUE, SUITE 300, NEW YORK NY 10170
James L Cox director 420 LEXINGTON AVENUE, SUITE 300, NEW YORK NY 10170
Aster Angagaw director 150 PEABODY PLACE, MEMPHIS TN 38103
Jacque J Sokolov director
David F Wurtman officer: Chief Medical Officer ONE GRAND CENTRAL PLACE, SUITE 4600, NEW YORK NY 10165